Novartis arthritis drug fails to prove it is significantly better than rival

sonos sonos One (Gen 2) - Voice Controlled Smart Speaker with Amazon Alexa Built-in - Black read more

Novartis arthritis drug fails to prove it is significantly better than rival

FILE PHOTO: Swiss drugmaker Novartis' logo is seen in Stein

More

ZURICH (Reuters) - A clinical trial of Novartis's Cosentyx drug has failed to prove it is significantly better than a rival treatment for a type of arthritis, the Swiss company said on Friday.

Novartis said Cosentyx, when used to treat active psoriatic arthritis, "narrowly missed statistical significance for superiority" versus Humira, a drug made by AbbVie.

"While Cosentyx narrowly missed statistical significance for superiority.... it showed numerically higher results versus Humira," Novartis said following the results of a head-to-head trial.

sonos sonos One (Gen 2) - Voice Controlled Smart Speaker with Amazon Alexa Built-in - Black read more

Psoriatic arthritis, an inflammatory disease affecting the joints, is a condition which affects around 50 million people worldwide.

This week U.S. regulators halted a trial of Novartis's Zolgensma treatment after an animal study raised safety concerns.

(Reporting by John Revill; Editing by Michael Shields)

all right reserved for yahoo news

Get the latest news delivered to your inbox

Follow us on social media networks

PREV Gallery: The best photos from around the world mogaznewsen
NEXT WIDER IMAGE-Winter poses new threat to migrants in Bosnian forest camp